{"id":"bcl2","name":"BCL-2","symbol":"BCL2","route":"/targets/bcl2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:990","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171791","uniprot":"https://www.uniprot.org/uniprotkb/P10415/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P10415","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4860","open-targets":"https://platform.opentargets.org/target/ENSG00000171791","civic":"https://civicdb.org/genes/596/summary","oncokb":"https://www.oncokb.org/gene/BCL2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCL2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=BCL2","depmap":"https://depmap.org/portal/gene/BCL2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000171791-BCL2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/596","omim":"https://www.omim.org/entry/151430"}],"products":[{"id":"sonrotoclax","name":"Sonrotoclax","status":"approved","modality":"Small-molecule BCL-2 inhibitor (second generation)","route":"/drugs/sonrotoclax/"},{"id":"venetoclax","name":"Venetoclax","status":"approved","modality":"Small-molecule BCL-2 inhibitor","route":"/drugs/venetoclax/"}],"trials":[{"id":"nct04778397","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","nct":"NCT04778397","phase":"3"},{"id":"nct05079230","name":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","nct":"NCT05079230","phase":"3"},{"id":"sympatico","name":"SYMPATICO","nct":"NCT03112174","phase":"3","status":"positive"},{"id":"verona","name":"VERONA","nct":"NCT04401748","phase":"3","status":"negative"},{"id":"amplify","name":"AMPLIFY","nct":"NCT03836261","phase":"3","status":"positive"},{"id":"cll13-gaia","name":"CLL13 / GAIA","nct":"NCT02950051","phase":"3","status":"positive"},{"id":"sequoia","name":"SEQUOIA","nct":"NCT03336333","phase":"3","status":"positive"},{"id":"glow","name":"GLOW","nct":"NCT03462719","phase":"3","status":"positive"},{"id":"viale-a","name":"VIALE-A","nct":"NCT02993523","phase":"3","status":"positive"},{"id":"cll14","name":"CLL14","nct":"NCT02242942","phase":"3","status":"positive"},{"id":"murano","name":"MURANO","nct":"NCT02005471","phase":"3","status":"positive"},{"id":"nct03539744","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","nct":"NCT03539744","phase":"3","status":"active"},{"id":"nct05057494","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","nct":"NCT05057494","phase":"3","status":"active"},{"id":"nct05947851","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","nct":"NCT05947851","phase":"3","status":"recruiting"},{"id":"nct06846671","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","nct":"NCT06846671","phase":"3","status":"recruiting"},{"id":"nct06428019","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","nct":"NCT06428019","phase":"3","status":"recruiting"},{"id":"nct06943872","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","nct":"NCT06943872","phase":"3","status":"recruiting"},{"id":"nct07277231","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","nct":"NCT07277231","phase":"3","status":"recruiting"},{"id":"nct06742996","name":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac","nct":"NCT06742996","phase":"3","status":"recruiting"},{"id":"nct04965493","name":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","nct":"NCT04965493","phase":"3","status":"active"},{"id":"nct03844048","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","nct":"NCT03844048","phase":"3","status":"active"},{"id":"celestial-tncll","name":"CELESTIAL-TNCLL","nct":"NCT06073821","phase":"3","status":"active"},{"id":"nct04229979","name":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","nct":"NCT04229979","phase":"3","status":"active"},{"id":"nct07007312","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","nct":"NCT07007312","phase":"3","status":"recruiting"},{"id":"nct03801525","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","nct":"NCT03801525","phase":"2/3"},{"id":"nct04256317","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","nct":"NCT04256317","phase":"2/3","status":"recruiting"},{"id":"nct07255872","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","nct":"NCT07255872","phase":"2/3","status":"recruiting"},{"id":"nct07581002","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","nct":"NCT07581002","phase":"2/3","status":"recruiting"},{"id":"beat-aml-master-trial","name":"Beat AML Master Trial","nct":"NCT03013998","phase":"platform","status":"recruiting"},{"id":"myelomatch","name":"myeloMATCH","nct":"NCT05564390","phase":"platform","status":"recruiting"},{"id":"captivate","name":"CAPTIVATE","nct":"NCT02910583","phase":"2","status":"positive"},{"id":"nct07743112","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","nct":"NCT07743112","phase":"2","status":"recruiting"},{"id":"nct05951959","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","nct":"NCT05951959","phase":"2","status":"active"},{"id":"nct03314181","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","nct":"NCT03314181","phase":"2","status":"active"},{"id":"nct07154264","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","nct":"NCT07154264","phase":"2","status":"recruiting"},{"id":"nct06456463","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","nct":"NCT06456463","phase":"2","status":"active"},{"id":"nct06115135","name":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","nct":"NCT06115135","phase":"2","status":"recruiting"},{"id":"nct02966756","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","nct":"NCT02966756","phase":"2","status":"active"},{"id":"nct05963074","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","nct":"NCT05963074","phase":"2","status":"active"},{"id":"nct06524375","name":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","nct":"NCT06524375","phase":"2","status":"active"},{"id":"nct05952037","name":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","nct":"NCT05952037","phase":"2","status":"active"},{"id":"nct06637501","name":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","nct":"NCT06637501","phase":"2","status":"active"},{"id":"nct07024706","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","nct":"NCT07024706","phase":"2","status":"recruiting"},{"id":"nct05201066","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","nct":"NCT05201066","phase":"2","status":"active"},{"id":"nct06191263","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","nct":"NCT06191263","phase":"2","status":"recruiting"},{"id":"nct05433532","name":"Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients","nct":"NCT05433532","phase":"2","status":"completed"},{"id":"nct05479994","name":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","nct":"NCT05479994","phase":"2","status":"active"},{"id":"nct02899052","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","nct":"NCT02899052","phase":"2","status":"active"},{"id":"nct04895436","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","nct":"NCT04895436","phase":"2","status":"recruiting"},{"id":"nct07387471","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","nct":"NCT07387471","phase":"2","status":"active"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"ascertain-v","name":"ASCERTAIN-V","nct":"NCT04657081","phase":"1/2","status":"positive"},{"id":"nct05471843","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","nct":"NCT05471843","phase":"1/2","status":"active"},{"id":"nct04988555","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","nct":"NCT04988555","phase":"1/2","status":"recruiting"},{"id":"nct04973605","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","nct":"NCT04973605","phase":"1/2","status":"recruiting"},{"id":"nct04771130","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","nct":"NCT04771130","phase":"1/2","status":"recruiting"},{"id":"nct05520567","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","nct":"NCT05520567","phase":"1/2","status":"active"},{"id":"nct05428969","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","nct":"NCT05428969","phase":"1/2","status":"active"},{"id":"nct06634589","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","nct":"NCT06634589","phase":"1/2","status":"recruiting"},{"id":"nct06697184","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","nct":"NCT06697184","phase":"1/2","status":"recruiting"},{"id":"nct05211570","name":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","nct":"NCT05211570","phase":"1/2","status":"recruiting"},{"id":"nct03850574","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","nct":"NCT03850574","phase":"1/2","status":"recruiting"},{"id":"nct06382168","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","nct":"NCT06382168","phase":"1/2","status":"recruiting"},{"id":"nct04086264","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","nct":"NCT04086264","phase":"1/2","status":"active"},{"id":"nct05673057","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","nct":"NCT05673057","phase":"1/2","status":"active"},{"id":"nct07520006","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","nct":"NCT07520006","phase":"1/2","status":"recruiting"},{"id":"nct04588922","name":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","nct":"NCT04588922","phase":"1/2","status":"recruiting"},{"id":"nct04068597","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","nct":"NCT04068597","phase":"1/2","status":"recruiting"},{"id":"nct04581512","name":"Study to Evaluate the Safety and Tolerability of EP0042","nct":"NCT04581512","phase":"1/2","status":"recruiting"}],"pathways":["bcr-signalling","basal-cell-carcinoma-signalling","drug-tolerant-persisters","extrinsic-apoptosis-death-receptors","ferroptosis-cell-death","apoptosis-bcl2","micrornas-in-cancer","mitotic-spindle-checkpoint","sclc-signalling","germinal-centre-reaction","p53-mdm2-axis","transcription-addiction"],"companies":["abbvie","ascentage-pharma","beone","roche-genentech"],"keyPapers":["paper-amplify-acalabrutinib-venetoclax-nejm-2025","paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-viale-a-venetoclax-azacitidine-nejm-2020","paper-cll14-venetoclax-obinutuzumab-nejm-2019","paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","paper-murano-venetoclax-rituximab-nejm-2018","paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004","paper-rosenwald-molecular-profiling-dlbcl-nejm-2002"],"hotspots":[{"label":"G101V","position":101,"kind":"resistance","drugs":["sonrotoclax"]},{"label":"D103Y / F104L","position":103,"kind":"resistance","drugs":["sonrotoclax"]}],"openQuestions":[{"id":"bcl2-fixed-duration","question":"Is fixed-duration venetoclax-based therapy curative for a subset of CLL, and who needs retreatment?","stage":"clinical","actor":"clinic","source":{"label":"CLL14, NEJM 2019","url":"https://doi.org/10.1056/NEJMoa1815281"}}],"assays":[],"resistance":[{"class":"btk-inhibitor","mechanism":"BTK C481S","category":"on-target"},{"class":"btk-inhibitor","mechanism":"BTK L528W and T474I after a non-covalent inhibitor","category":"on-target"},{"class":"btk-inhibitor","mechanism":"PLCG2 gain of function","category":"bypass"},{"class":"bcl2-inhibitor","mechanism":"BCL2 G101V and other binding-groove mutations","category":"on-target"},{"class":"bcl2-inhibitor","mechanism":"Dependence shifts to MCL1 or BCL-xL","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}